Adaptive clinical trials: The promise and the caution

Journal of Clinical Oncology

Volumn 29, Issue 6, 2011, Pages 606-609

  Berry, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL TRIAL (TOPIC); DRUG RESEARCH; EDITORIAL; HUMAN; MEDICAL RESEARCH; METHODOLOGY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; REMISSION;

HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 79952079839     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.2685     Document Type: Editorial

References (19)

1. Berry DA: Bayesian clinical trials. Nat Rev Drug Discov 5:27-36, 2006
2. Berry DA: Statistical innovations in cancer research, in Hong WK, Bast RC Jr, Hait WN, et al (eds): Holland-Frei Cancer Medicine (ed 8). London, UK, BC Decker, 2009, pp 446-463
3. Berry DA: Introduction to Bayesian methods III: Use and interpretation of Bayesian tools in design and analysis. Clin Trials 2:295-300, 2005
4. Berry DA: The hazards of endpoints. J Natl Cancer Inst 102:1376-1377, 2010
5. Korn EL, Freidlin B: Outcome-adaptive randomization: Is it useful? J Clin Oncol 29:771-776, 2011
6. Giles FJ, Kantarjian HM, Cortes JE, et al: Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21:1722-1727, 2003 (Pubitemid 46638583)
7. Thompson WR: On the likelihood that one unknown probability exceeds another in view of the evidence of the two samples. Biometrika 25:285-294, 1933
8. Medical Research Council: Streptomycin treatment of pulmonary tuberculosis. Br Med J 2:769-782, 1948
9. Chalmers I: Why the 1948 MRC trial of streptomycin for pulmonary tuberculosis used treatment allocation based on random numbers. The James Lind Library, 2010. http://www.jameslindlibrary.org/trial-records/20th-Century/1940s/ MRC-bmj/chalmers.html
10. Chalmers I: Joseph Asbury Bell and the birth of randomized trials. The James Lind Library, 2006. http://www.jameslindlibrary.org/trial-records/20th- Century/1940s/bell-1941/bell-commentary.php
11. Biswas S, Liu DD, Lee JJ, et al: Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials 6:205-216, 2009
12. McCarthy A: Is it time to change the design of clinical trials? CureToday.com, Summer, 2006. http://www.curetoday.com/index.cfm/fuseaction/ article.show/id/2/article-id/371
13. Institute of Medicine: A national cancer clinical trials system for the 21st century - Reinvigorating the NCI Cooperative Group Program. Nass SJ, Moses HL, Mendelsohn J (eds). Washington, DC, National Academies Press, 2010. http://www.nap.edu/catalog.php?record-id=12879
14. Zhou X, Liu S, Kim ES, et al: Bayesian adaptive design for targeted therapy development in lung cancer: A step toward personalized medicine. Clin Trials 5:181-193, 2008
15. Barker AD, Sigman CC, Kelloff GJ, et al: I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100, 2009
16. Winslow R: A new Rx for medicine. Wall Street Journal. Oct 2, 2010. http://online.wsj.com/article/SB10001424052748703882404575520190576846812.html
17. Adaptive Design Clinical Trials for Drugs and Biologics, Draft Guidance for Industry, February 2010. http://www.fda.gov/downloads/ DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf
18. Gaydos B, Anderson K, Berry D, et al: Good practices for adaptive clinical trials. Drug Inf J 43:539-556, 2009
19. Cook JD: The effect of population drift on adaptively randomized trials. UT MD Anderson Cancer Center Department of Biostatistics Working Paper 39. Berkeley, CA, Berkeley Electronic Press, 2007. http://www.bepress.com/ mdandersonbiostat/paper39/